RNAC
Cartesian Therapeutics, Inc.
$9.46
-0.21 (-2.17%)
At close · Jul 10
Market Cap
$277.95M
Shares
29,381,514
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$9.46
Open$9.60
Day$9.08–9.73
52W$5.60–14.56
Avg vol 30d399K
Short int1.9M · 6.4% float · 4.9d
Short vol62%
Last earningsMay 8, 2025
DataJan 2020–Jul 2026
Filing10-Q · Apr 30
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Apr 30, 2026
Equibles Rating
blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical
Neutral
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 15 · calm
Equity put/call 0.55
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+23%
above
Price vs 50-day avg
+16%
above
RSI (14)
53
neutral
MACD trend
Negative
52-week position
43%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+27%
trailing
6-month return
+29%
trailing
YTD return
+31%
this year
Relative strength
+19%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $8 › 200d $8 — 50d above 200d
Institutional flow
Distributing
1 of 82 funds reported for Jun 30 · net -607 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
6.42% of float · ▼ -2.1% MoM · 4.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
82 holders — near 3-yr high, broad support
Squeeze score
74
high risk · 0–100
Fundamentals
Revenue growth
−93%
Y/Y
EPS growth
−12%
Y/Y
Free cash flow
$-79.4M
Balance sheet
$125.1M
net cash
Quant / Vol
risk profile
Volatility
86%
annualized · 1-yr
Max drawdown
−57%
past year
ATR
9.5%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+23%
Bullish
Price vs 50-day avg
+16%
Bullish
RSI (14)
53
Neutral
MACD trend
Negative
Bearish
52-week position
43%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $8 › 200d $8 — 50d above 200d
Institutional flow
Distributing
1 of 82 funds reported for Jun 30 · net -607 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
6.42% of float · ▼ -2.1% MoM · 4.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
82 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $6
Now $9 · 43%
52-wk high $15
vs 200-day avg +23%
vs 50-day avg +16%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
RNAC
this stock
Cartesian Therapeutics, Inc.
|
$277.95M | +31.2% | +49.6% | — | 6.4% |
|
ONC
BeOne Medicines Ltd.
|
$431.70B | -1.7% | +22179.2% | 878.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$123.19B | +7.1% | +46.2% | 28.8 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.67B | -13.8% | +20.8% | 16.2 | 3.3% |
|
ARGX
Argenx SE
|
$54.85B | +4.4% | — | — | 2.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| RNAC | -10.7% | +27.3% | +28.5% | -9.2% | +31.2% |
| SPY | +1.4% | +4.1% | +9.1% | +1.1% | +10.7% |
| vs SPY | -12.0% | +23.3% | +19.5% | -10.3% | +20.5% |